SuperworthXilio Therapeutics shares outstanding XLO
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 19.4M
- On a year earlier
- +181.7%
- more shares
Xilio Therapeutics had 19.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 181.7% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 10.8M | +135% |
| FY2024 | 4.6M | +135% |
| FY2023 | 2M | +1% |
| FY2022 | 2M | +4058% |
| FY2020 | 47.1K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 19.4M | +182% | |
| Q1 FY26 | 16.3M | +206% | |
| Q4 FY25 | 10.8M | +135% | |
| Q3 FY25 | 10.3M | +127% | |
| Q2 FY25 | 6.9M | +67% | |
| Q1 FY25 | 5.3M | +168% | |
| Q4 FY24 | 4.6M | +135% | |
| Q3 FY24 | 4.5M | +131% | |
| Q2 FY24 | 4.1M | +110% | |
| Q1 FY24 | 2M | +2% | |
| Q4 FY23 | 2M | +1% | |
| Q3 FY23 | 2M | +0% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Xilio Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.